Menopause and Perimenopause Hormone Therapy in Chicagoland

Through perimenopause and into menopause, the ovaries gradually produce less estrogen. That decline is what drives the changes most women notice first: hot flashes, night sweats, sleep that breaks up, and vaginal dryness or discomfort. Menopause itself is a normal life stage rather than an illness, and the U.S. Food and Drug Administration describes it in exactly those terms.

Hormone therapy replaces some of the estrogen the ovaries no longer make, which is what eases the symptoms that decline causes. The estrogen used here is estradiol, the same form of estrogen the body produces. It can be prescribed for you to take at home, or given as an in-office injection once you are an established patient.

Dosing is guided primarily by how you respond. Current practice is to start at a low dose, then adjust against your symptoms and how well you tolerate it, with lab work used to inform the picture rather than to chase a number. Your nurse practitioner draws a panel before anything is prescribed and reads it alongside your symptoms and medical history. Two women with similar symptoms can need very different doses, and the same woman often needs a different dose a year later.

If you still have a uterus, estrogen is not prescribed on its own. A progestogen is added to the plan, because estrogen used alone thickens the lining of the uterus over time. That pairing is a standard part of how hormone therapy is prescribed, and your nurse practitioner will explain which combination applies to you.

It helps to separate two things: what hormone therapy is approved for as a class of medication, and what any individual plan is expected to do for you. The first is a matter of public record. The second is a conversation with your clinician.

The FDA has approved hormone therapy products for moderate to severe hot flashes and night sweats, known clinically as vasomotor symptoms; for vaginal dryness and discomfort and the related vulvar and urinary changes that follow lower estrogen; and for preventing bone loss after menopause. Those are the labeled indications for the drug class, stated by the agency itself.

Timing is part of the labeling too. The FDA’s recommendation is that systemic hormone therapy be started within 10 years of the onset of menopause, or before age 60. That is guidance shaping the discussion, not a cutoff applied at the door. Women outside that window still come in, and the conversation simply weighs the picture differently.

What we will not do is tell you in advance what your result will be. Symptom response varies, dosing takes adjustment, and some women decide hormone therapy is not the route they want. The consultation exists to work that out with your own labs and history in front of you, rather than from an average.

Every plan starts the same way, with a consultation that includes a physical exam and lab work. That visit is where the hormone panel is drawn and where a prescription plan is written. It is a paid medical visit with labs attached, not a complimentary consultation.

From there the program has a few moving parts:

• Prescription hormone therapy: your nurse practitioner writes a prescription you fill and take at home. Hormones are purchased separately and are not included in any consultation fee.
• Estradiol office injection: a 5 mg injection given here about every 3 to 4 weeks, for established patients who have completed the full workup and consultation. These visits run about 15 minutes.
• Follow-up visits with labs: repeat testing and dose adjustment, priced according to whether your labs bill to insurance.

One thing our menu does not include is an estrogen pellet. The pellet service listed under hormone replacement is a testosterone pellet, which is a different hormone and a separate decision. It is covered on our testosterone replacement therapy page.

All of it is available at each of our four Chicagoland clinics: La Grange, Frankfort, Shorewood and Mount Greenwood. Injections and pellets are open to established patients only, so the consultation always comes first.

The initial consultation is scheduled for about 30 minutes. Beforehand you complete a symptoms of menopause intake form, which gives your nurse practitioner a structured picture of what you are actually experiencing rather than a general sense that something is off.

During the visit you can expect:

• A review of your symptoms, cycle history, personal and family medical history, and everything you currently take
• A physical exam
• A lab draw. The standard panel covers a complete blood count, estradiol and testosterone, with tests such as FSH, LH, prolactin or thyroid added when your history calls for them
• Prescription recommendations once your results are back

Two paths exist for the labs, and they change the price rather than the care. When your labs bill to insurance, the consultation is $99. When you pay cash for labs, the consultation including those labs is $285. You are told which applies before anything is drawn.

You will not usually leave the first visit with hormones in hand, because results have to come back first. The clinicians who run this service are the same nurse practitioners who lead our medical wellness line.

Hormone therapy is ongoing care rather than a single procedure with a finish line. The rhythm is set by the delivery route you and your nurse practitioner choose, and by what your repeat labs show.

Typical cadence:

• Estradiol office injection: about every 3 to 4 weeks, roughly a 15 minute visit
• Prescription therapy you fill: taken on the schedule your prescription sets, with no visit needed between follow-ups
• Follow-up visits with labs: scheduled around dose changes, then at the intervals your clinician sets

Symptom response is individual and we do not put a date on it. Some women notice changes within the first weeks of treatment, others need one or two dose adjustments before things settle, and some decide the route is not for them. That is what the follow-up visits are for: a dose change, repeat labs, or a different plan. Hair thinning is a common and separate concern through this stage, and we cover it in menopause and hair loss.

How long you stay on hormone therapy is a decision you revisit with your clinician rather than a fixed course. It is reviewed at each follow-up against your symptoms, your lab results and your own preferences.

Two estrogen delivery routes are available here once your workup is complete. Neither is better than the other in the abstract. They differ in how often you come in and in how quickly a dose can be changed.

A prescription you fill keeps dosing in your hands day to day, and a change takes effect with the next dose. It also depends on you remembering it. Estradiol comes in several forms, and the specific one you are prescribed is chosen with your nurse practitioner at the consultation, based on your history, your labs and what you would actually keep up with.

The estradiol office injection is given here about every 3 to 4 weeks. There is nothing to remember between visits and a clinician sees you regularly, but it means a standing appointment, and the dose is fixed for that interval.

Many women start on one and move to the other while dosing is being worked out. What you choose is not permanent, and switching routes is a normal part of ongoing care.

Hormone pellets are a separate question. The pellet on our menu delivers testosterone, not estrogen, so it is not an alternative route for estrogen therapy. It is implanted, which means the dose cannot be reduced until it wears off. If it comes up in your consultation, your nurse practitioner will walk through it as its own decision. See testosterone replacement therapy.

If you looked into hormone therapy at any point in the last twenty years, you probably met a stark warning box and a great deal of caution, most of it tracing back to the Women’s Health Initiative trial. That labeling has begun to change, and it is worth knowing exactly what did and did not change.

On November 10, 2025 the FDA began removing the broad boxed warnings from menopausal hormone therapy products. On February 12, 2026 the agency approved the first batch of labeling changes, covering six products across all four categories of menopausal hormone therapy. Twenty nine companies had submitted proposed changes, so this is a rollout in progress rather than a finished class-wide switch. The risk statements removed from those boxed warnings were cardiovascular disease, breast cancer and probable dementia.

What did not change matters just as much. The FDA did not remove the boxed warning for endometrial cancer on systemic estrogen-alone products, which is precisely why a progestogen belongs in the plan when you still have a uterus. Just as important, moving a risk statement out of a warning box is not the same as the risk disappearing: blood clots, stroke, heart attack and breast cancer remain part of the labeled safety picture for systemic estrogen and are weighed against your own history.

We are not going to turn a regulatory update into a promise about your health. What it does mean is that the conversation with your nurse practitioner can be based on current labeling rather than on a warning box the agency has begun to revise.